newsfilter
← Latest News
GlobeNewswire·

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced neuroscience